NS 015
Alternative Names: NS-015Latest Information Update: 29 Jan 2025
Price :
$50 *
At a glance
- Originator NeuShen Therapeutics
- Class Antidepressants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Depressive disorders
Most Recent Events
- 08 Jan 2025 Preclinical trials in Depressive disorders in China (unspecified route) before January 2024 (Neushen Therapeutics pipeline, January 2024)
- 08 Jan 2025 Neushen Therapeutics anticipates IND filing in Depressive disorders (Neushen Therapeutics pipeline, September 2024)